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Bloodstream infections (BSI) caused by Candida spe-
cies are an important cause of morbidity and mortality 
in hospitalised patients worldwide (Zaoutis et al. 2005, 
Odds et al. 2007, Pfaller & Diekema 2007, Hsueh & Ruan 
2009). Candidaemia is generally difficult to diagnose and 
treat and mortality rates remain at approximately 50%, 
with great costs to the healthcare system (Gudlaugsson et 
al. 2003, Colombo et al. 2008, Arnold et al. 2010).
In Brazil, several investigators have described the 
epidemiology of candidaemia in tertiary care hospitals. 
The incidence rate of candidaemia continues to be high, 
with incidence rates ranging from 1.27-2.49 per 1,000 ad-
missions (Colombo et al. 2006, 2007, França et al. 2008, 
Girão et al. 2008, Motta et al. 2010, Pereira et al. 2010). 
Conversely, studies undertaken in tertiary hospitals in 
the United States and several European countries have 
shown lower incidence rates, ranging from 0.28-0.96 
and 0.02-1.08 per 1,000 admissions, respectively (Hajjeh 
et al. 2004, Tortorano et al. 2004, Almirante et al. 2005, 
Zilberberg et al. 2008, Poikonen et al. 2010, Arendrup et 
al. 2011, Das et al. 2011).
Almost all of the previous Brazilian candidaemia 
studies have been conducted during short periods of 
time, which preclude proper conclusions regarding tem-
poral trends of Candida distribution, incidence rates and 
epidemiological characteristics of the populations (Nuc-
ci et al. 2010). This retrospective study was conducted 
to evaluate the historical trends of incidence rates and 
epidemiological characteristics of all of the candidaemia 
cases documented at a large tertiary care hospital in Bra-
zil during an 11-year period from 1994-2004.
SUBJECTS, MATERIALS AND METHODS
Surveillance - This study has merged three databases 
that include information regarding all candidaemia pa-
tients admitted to Hospital São Paulo between January 
1994-December 2004. Hospital São Paulo is a university-
affiliated tertiary care centre with 743 beds, of which 121 
are for the intensive care unit in São Paulo, Brazil. Hospi-
tal São Paulo attends to cases of high complexity, includ-
ing solid organ and haematopoietic stem cell transplants.
The databases were composed of clinical and labora-
tory data. Briefly, an investigator was trained to search 
for positive blood cultures in the microbiology labora-
tory on a daily basis. When a candidaemia episode was 
identified, the clinical and epidemiological data were 
prospectively collected in a standardised case report 
form. The form contained the following information: 
age, gender, date of admission, ward, date of candidae-
mia, underlying conditions, exposure to invasive medi-
cal procedures, use of antibiotics or corticosteroid drugs, 
management of candidaemia (antifungal treatment, 
catheter removal) and outcome (in-hospital mortality). 
Hospital laboratory audits were performed periodically 
to ensure that no cases of candidaemia were missed. In 
addition, medical records audits were sporadically per-
formed on 10% of the cases to verify the accuracy and 
completeness of the data. The protocol was approved by 
the local Ethical Committee.
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Candida species are an important cause of bloodstream infections (BSI). To evaluate the epidemiological, clini-
cal and microbiological aspects of two cohorts {1994-1999 [period 1 (P1)]; 2000-2004 [period 2 (P2)]} of candidae-
mic patients, we performed a retrospective analysis from a laboratory-based survey. A total of 388 candidaemias 
were identified, with an incidence of 0.20/1,000 patient-days and a significant increase in P2 vs. P1 (0.25 vs. 0.15, p 
= 0.04). Cancer and prior antibiotic use were frequent and Candida albicans was the most prevalent species found 
(42.4%). Resistance to fluconazole was found in 2.47% of the strains. No differences were observed in the species dis-
tribution of Candida during the study periods. In the P2 cohort, there were higher prevalence of elderly individuals, 
cardiac, pulmonary and liver diseases, renal failure, central venous catheters and antibiotic therapy. In P1, there 
were higher prevalence of neurological diseases and chemotherapy. The crude mortality was 55.4%. In conclusion, 
our incidence rates remained high. Furthermore, the distribution pattern of Candida species and the fluconazole re-
sistance profile remained unchanged. Moreover, we found a clear trend of higher prevalence of candidaemia among 
the elderly and among patients with comorbidities. Finally, it is necessary to discuss strategies for the prevention 
and control of Candida BSI in Brazil.
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Case definition - An episode of candidaemia was 
defined as the incident isolation of Candida spp from a 
blood culture (BACTEC system) of a patient with symp-
toms suggestive of BSI. Briefly, a fever was defined as 
an axillary temperature > 37.8ºC, hypotension as sys-
tolic blood pressure < 90 mmHg and neutropaenia as an 
absolute neutrophil count < 500/mm3. The demograph-
ics, clinical characteristics, risk factors and outcomes 
(in-hospital mortality) were compared between the two 
periods. Candidaemia occurring > 30 days after the inci-
dent isolation was defined as a new episode.
Yeast identification - All Candida species recovered 
from the blood cultures were sent to the Special Mycol-
ogy Laboratory at Federal University of São Paulo for 
species identification and determination of antifungal 
susceptibility. The isolates were identified according 
to their microscopic morphology on corneal Tween 80 
agar and by biochemical tests using the ID 32C system 
(bioMérieux). Susceptibility testing to fluconazole was 
performed by the broth microdilution assay according to 
the methods recommended by the Clinical and Labora-
tory Standards Institute (CLSI 2002). The isolates with 
minimal inhibitory concentration (MICs) of 8 µg/mL 
fluconazole were considered susceptible. The isolates 
with MICs of 16 and 32 µg/mL were considered suscep-
tible in a dose-dependent (SDD) manner and the isolates 
with MICs of 64 µg/mL were considered resistant.
Statistical analysis - The number of admissions and 
patient-days was collected. The incidence rates were cal-
culated as the number of candidaemias per 1,000 admis-
sions and per 1,000 patient-days. The overall incidence 
was determined using summed denominators of patient-
days and admissions to calculate pooled mean rates. The 
analysis of the incidence rates and species distribution 
patterns were arbitrarily performed considering two in-
tervals: 1994-1999 [period 1 (P1)] and 2000-2004 [peri-
od 2 (P2)]. The statistical analysis was performed by the 
X2 or Fisher’s exact test for categorical variables or the 
Student’s t test for continuous variables with Statistical 
Package for the Social Sciences software 15.0 (Chicago, 
IL). All of the tests of statistical significance were two-
sided, with a significance level set at 0.05.
RESULTS
We detected a total of 388 episodes of candidaemia 
during the surveillance period. Of these, 60.3% of the 
patients were males and the mean and median age was 
32.4 and 30 years, respectively (range 0-99 years). The 
overall incidence rate was 1.20 episodes per 1,000 ad-
missions and 0.20 episodes per 1,000 patient-days. Fig. 1 
shows the incidence rate of candidaemia, which ranged 
from 0.68-1.84 cases per 1,000 admissions and 0.09-0.37 
cases per 1,000 patient-days.
The demographics, clinical characteristics, risk fac-
tors and outcomes (in-hospital mortality) are displayed 
in Table I. Most of the candidaemia cases occurred in 
the adult intensive care unit (85/388, 21.9%) or the 
paediatric intensive care unit (66/388, 17%). Underly-
ing diseases were present in 97.4% (378/388) of the pa-
tients. Cancer was the most frequent underlying disease 
(103/378, 31.7%), followed by renal failure (43/378, 11%), 
pulmonary disease (32/378, 8.2%) and diabetes mellitus 
(31/378, 7.9%). Overall, the use of prior antibiotic therapy 
was documented in 93.2% (362/388) of the cases. The in-
sertion of a central line was reported in 72.9% (283/388) 
of the patients. The presence of clinical manifestations 
could be evaluated in only 302 patients. Fever, hypoten-
sion and hypothermia were present in 88.4% (267/302), 
6.9% (21/302) and 17.2% (52/302) of the patients, respec-
tively. Candida albicans was the most prevalent species 
found (165 cases, 42.4%), followed by Candida tropicalis 
(106 cases, 27.3%) and Candida parapsilosis (85 cases, 
21.9%). Candida glabrata and Candida krusei comprised 
only 4.4% and 1% of the cases, respectively (Table II).
Susceptibility testing to fluconazole was undertaken 
for 323 (83.2%) Candida strains. SDD and resistance 
were found in 2.47% (8/323) of the strains. The spe-
cies that were most prevalent for the SDD or resistance 
phenotypes were C. krusei (2/3, 66.7%) and C. glabrata 
(2/15, 13.3%). No resistant isolates were found among 
the C. albicans, C. parapsilosis or C. tropicalis strains. 
Overall, antifungal therapy was administered for 69.5% 
(270/388) of the cases. Of these, amphotericin B desoxi-
colate and fluconazole were used by 88.8% (239/270) 
and 11.1% (30/270) of the patients, respectively.
There was a significant increase in the incidence of 
candidaemia per 1,000 patient-days in P2 compared with 
P1 (0.25 vs. 0.15, p = 0.04). In contrast, the difference in 
incidence rates of candidaemia per 1,000 admissions be-
tween the two periods was not significant (1.05 vs. 1.32, 
p = 0.17), as illustrated in Fig. 1.
The mean age of the patients with candidaemia was 
27.2 years and 36.3 years for P1 and P2, respectively. 
In P2, there were higher prevalence of central venous 
catheters and antibiotic therapy compared with P1. In P2 
we observed higher prevalence of individuals with older 
age, cardiac disease, pulmonary disease, liver disease 
and renal failure. Conversely, in the first period, there 
was a higher prevalence of patients with neurological 
disease and exposure to chemotherapy. The main epide-
miologic characteristics of the patients analysed in the 
two study periods are summarised in Table I.
The distribution of the Candida species causing candi-
daemia was evaluated to identify possible trends through-
Fig. 1: incidence rates of candidaemia at Hospital São Paulo 
(1994-2004). Asterisks mean significant differences between 
the two periods.
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out the study period. We found no differences in the dis-
tribution of the four major species of Candida (Fig. 2).
We noted that a significant number of candidaemic 
patients in both study periods were not treated: 31% 
(52/165 cases) vs. 30% (66/223 cases), respectively (p = 
0.68). The average rate of crude in-hospital mortality was 
55.4%. The in-hospital mortality rate was 53.9% (89/165) 
for P1 and 56.5% (126/223) for P2 (p = 0.61). The average 
time between the diagnosis of candidaemia and death 
was 15 days for P1 and 19 days for P2 (p = 0.48).
DISCUSSION
The present study has consolidated important epide-
miologic findings of candidaemia in our institution. We 
found an incidence rate of 1.20 infections per 1,000 hos-
pital admissions. This is similar to the incidence rates 
published by other groups in our country (Colombo et 
al. 2007, França et al. 2008, Girão et al. 2008, Nucci et 
al. 2010), but consistently higher than studies conducted 
in the northern hemisphere. Epidemiological studies 
performed in tertiary care hospitals in Europe and the 
United States have shown incidence rates ranging from 
0.02-1.08 cases per 1,000 hospital admissions (Hajjeh et 
al. 2004, Tortorano et al. 2004, Almirante et al. 2005, 
Zilberberg et al. 2008, Poikonen et al. 2010, Arendrup et 
al. 2011, Das et al. 2011).
The explanations for the high rates of candidaemia 
at our institution were not specifically addressed in our 
study, but possible factors, such as differences in the 
availability of resources for medical care and training 
programs, difficulties in the implementation of infection 
control programs in hospitals in developing countries, 
the limited number of healthcare workers for assisting 
patients in critical care units and less aggressive empiri-
cal antifungal therapy practices and prophylaxis for high-
risk patients have been discussed elsewhere (Colombo et 
al. 2007). In addition, we found a significant increase in 
the candidaemia incidence rate per 1,000 patient-days in 
the second period of data collection compared with the 
first period. Comparing the two periods, we observed 
that P2 had a higher prevalence of patients exhibiting the 
following comorbidities: cancer, renal failure, lung dis-
ease, diabetes mellitus and cardiac disease. The higher 
prevalence of older patients, as well as individuals with 
multiple degenerative diseases in P2 may help explain 
the higher incidence of candidaemia in that period. This 
TABLE I
Comparative analysis of the demographic and clinical characteristics of 388 cases  
of candidaemia documented in period 1 (P1) (1994-1999) and period 2 (P2) (2000-2004)
Variables
P1
n = 165
n (%)
P2
n = 223
n (%)
Overall
n = 388
n (%) p
Male gender 99 (60) 135 (60.5) 234 (60.3) 0.915
Mean age, years (range) 27.2 36.3 32.4 (0-99) 0.002
Length of hospital stay until candidaemia, days (range) 19 19 19 (0-367) 0.218
Median time until death, days 7 8 8 0.481
Underlying diseases
   Cancer 44 (26.7) 79 (35.4) 123 (31.7) 0.067
   Neutropaenia 29 (17.6) 32 (14.3) 61 (15.7) 0.388
   Cardiac disease 4 (2.4) 23 (10.3) 27 (6.9) 0.003
   Pulmonary disease 0 32 (14.3) 32 (8.2) < 0.001
   Liver disease 3 (1.8) 16 (7.2) 19 (4.8) 0.016
   Neurologic disease 11 (6.7) 4 (1.8) 15 (3.8) 0.014
   Diabetes mellitus 12 (7.3) 19 (8.5) 31 (7.9) 0.654
   Renal failure 12 (7.3) 31 (13.9) 43 (11) 0.040
   Organ transplant recipients 3 (1.8) 7 (3.1) 10 (1.8) 0.523
   Human immunodeficiency virus infection 5 (3) 4 (1.8) 9 (2.3) 0.507
Coexisting exposures
   Use of corticosteroids 69 (41.8) 105 (47.1) 174 (44.8) 0.302
   Dialysis 11 (6.7) 21 (9.4) 32 (8.2) 0.330
   Chemotherapy 28 (17) 22 (9.9) 50 (12.8) 0.039
   Previous surgery 66 (40) 95 (42.6) 161(41.4) 0.607
   Central venous catheter 113 (68.5) 170 (76.2) 283 (72.9) 0.089
   Parenteral nutrition 66 (40) 73 (32.7) 139 (35.8) 0.140
   Prior antibiotic therapy 154 (93.3) 208 (93.3) 362 (93.2) 0.981
No antifungal treatment 52 (31) 66 (30) 118 (30.4) 0.680
Crude in-hospital mortality 89 (53.9) 126 (56.5) 215 (55.4) 0.610
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significant increase in the incidence rate between the 
two periods was not observed when using the other de-
nominator (number of admissions). This fact might be 
explained by the higher number of admissions in P2.
The median age of the cases enrolled in our study 
was 29 years, a finding that is in accordance with other 
Brazilian studies, in which paediatric patients accounted 
for a large number of candidaemia cases (Colombo et al. 
2006, 2008, França et al. 2008). Indeed, a total of 151 pa-
tients (38.9%) with candidaemia were < 13 years old. This 
statistic corroborates the finding of high participation of 
paediatric patients in different candidaemia casuistic pub-
lished in Brazil. The mean age of patients with candidae-
mia observed in P2 was slightly higher than P1. However, 
the percentage of adults in our candidaemia study is still 
proportionally lower than that found in developed coun-
tries (Colombo et al. 2008, Nucci et al. 2010).
In this study, nearly 40% of the candidaemia cases 
occurred in intensive care units (adult and paediatric). 
This finding is in accordance with previous surveil-
lance studies, in which haematogenous candidiasis has 
frequently been found in intensive care units (Blot et al. 
2001, Blumberg et al. 2001, Kibbler et al. 2003, Fujitani 
et al. 2006, Girão et al. 2008).
Cancer, renal failure, lung disease, diabetes mellitus 
and cardiac disease were the major underlying diseases 
among patients with candidaemia in our study, a finding 
that is consistent with other studies (Nucci et al. 2010). 
Potential risk factors associated with candidaemia, such 
as the previous use of antimicrobial drugs, central lines, 
the use of corticosteroids, parenteral nutrition and sur-
gery, were also identified in our study (Wey et al. 1988, 
Colombo et al. 2006, 2008, Sofair et al. 2006, St-Ger-
main et al. 2008, Poikonen et al. 2010).
C. albicans, C. parapsilosis and C. tropicalis were 
the most prevalent Candida species in our study. These 
data are similar to previous studies conducted in Brazil 
prior to 2005, in which C. tropicalis and C. parapsilo-
sis were the most prevalent non-albicans species caus-
ing candidaemia (Colombo et al. 1999, 2006, Costa et 
al. 2000, Girão et al. 2008, Nucci et al. 2010). However, 
studies published after 2005 have found that C. glabrata 
is emerging as an important aetiologic agent of candi-
daemia in some Brazilian medical centres (Pasqualotto 
et al. 2008, Sampaio Camargo et al. 2010).
Fluconazole resistance was a rare finding in our 
study and restricted to a few isolates, mainly represented 
by C. krusei and C. glabrata strains. It is noteworthy that 
we did not find fluconazole-resistant strains among the 
three most prevalent species in our study (C. albicans, C. 
parapsilosis and C. tropicalis).
Only 69.5% of the patients received antifungal treat-
ment after the diagnosis of candidaemia. The reasons for 
this worrisome situation were not evaluated. However, 
we suspect that difficulties in establishing an early di-
agnosis of candidaemia played a major role. The crude 
mortality of candidaemia was 55.4%, a finding that is 
compatible with results from other Brazilian studies 
(Colombo et al. 2006, 2008, Girão et al. 2008). It is note-
worthy that this mortality rate was similar in both study 
periods (approximately 55%). Considering that antifun-
gal resistance was rare in our study, the factors related 
to unfavourable outcomes were likely the severity of the 
illness and late diagnosis of candidaemia.
In conclusion, our study demonstrated a significant 
increase in the incidence of candidaemia in a tertiary 
care hospital in Brazil. Overall, our incidence rates have 
remained higher than those reported in medical centres 
of the northern hemisphere. The distribution pattern 
and fluconazole resistance profile of Candida species 
have remained unchanged. Moreover, we found a clear 
trend of higher prevalence of candidaemia among elder-
ly patients and patients with comorbidities. Finally, it is 
clear that new strategies for the prevention and control 
of haematogenous Candida infections should be dis-
cussed in our region.
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